United Arab Emirates Newborn Screening Software Market Size & Outlook, 2026-2034
United Arab Emirates Newborn Screening Software Market Insights
- As per Reed Intelligence insights, the United Arab Emirates Newborn Screening Software Market stood at USD 71.56 Million in 2025 and is anticipated to grow to USD 141.16 Million by 2034.
- The United Arab Emirates market is expected to advance at a CAGR of 7.88% from 2026 through 2034.
- In 2025, Instruments accounted for the highest share of the By Product market size.
- During the forecast period, Reagents is set to register the highest growth, making it the most lucrative By Product segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- United Arab Emirates accounted for 5.08% of the global Newborn Screening Software Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Middle East and Africa, United Arab Emirates is forecasted to dominate the regional Newborn Screening Software Market size by 2034.
- South Africa will be the fastest-growing market in Middle East and Africa, projected to achieve USD 30.7 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 71.56 Million |
| Market Size In 2034 | USD 141.16 Million |
| Largest segment | Instruments |
| Units | Revenue in USD Million |
| CAGR | 7.88% (2026-2034) |
| Segmnetation Covered | |
| By Product |
|
| By Technology |
|
| By Test Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Arab Emirates Newborn Screening Software Market By Product 2026-2034 (USD Million)
| By Product | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments | XX.x | XX.x | XX.x | 39.99 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reagents | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Arab Emirates Newborn Screening Software Market By Technology 2026-2034 (USD Million)
| By Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tandem Mass Spectrometry | XX.x | XX.x | XX.x | 21.52 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pulse Oximetry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme Based Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| DNA Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Arab Emirates Newborn Screening Software Market By Test Type 2026-2034 (USD Million)
| By Test Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Blood Spot Test | XX.x | XX.x | XX.x | 34.03 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CCHD | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hearing Screen | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.